Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Anxiety disorders, Seizures and Insomnia Diseases
4.2.2 Rise in Adoption of Generic Drugs
4.3 Market Restraints
4.3.1 Misuse of Benzodiazepine Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Alprazolam
5.1.2 Diazepam
5.1.3 Lorazepam
5.1.4 Clonazepam
5.2 By Application
5.2.1 Anxiety disorders
5.2.2 Seizures
5.2.3 Insomnia
5.2.4 Alcohol Withdrawal
5.3 By Time of Action
5.3.1 Ultra-short Acting
5.3.2 Short Acting
5.3.3 Long Acting
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amneal Pharmaceuticals LLC
6.1.2 Apotex Inc.
6.1.3 Aurobindo Pharma
6.1.4 Bausch Health Companies, Inc.
6.1.5 F.Hoffmann-La Roche Ltd.
6.1.6 H.Lundbeck A/S
6.1.7 Mylan, N.V.
6.1.8 Pfizer Inc.
6.1.9 Sun Pharmaceutical Industries Ltd.
6.1.10 Teva Pharmaceutical Industries Ltd.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS